ArriVent BioPharma (AVBP) Total Current Liabilities (2023 - 2026)

ArriVent BioPharma has disclosed Total Current Liabilities across 4 years of filings, most recently posting $25.0 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $25.0 million, up 92.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (up 92.97% YoY), and the FY2025 annual result was $25.9 million, up 50.2% from the prior year.
• Total Current Liabilities came in at $25.0 million for Q1 2026 at ArriVent BioPharma, down from $25.9 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.9 million in Q4 2025 to a low of $10.0 million in Q1 2024.
• The 4-year median for Total Current Liabilities is $16.2 million (2024), against an average of $17.1 million.
• Across the five-year window, Total Current Liabilities rose 29.83% in 2025 and jumped 92.97% in 2026, its largest moves.
• ArriVent BioPharma's Total Current Liabilities stood at $11.6 million in 2023, then surged by 48.61% to $17.3 million in 2024, then jumped by 50.2% to $25.9 million in 2025, then fell by 3.66% to $25.0 million in 2026.
• The last three Total Current Liabilities figures came in at $25.0 million (Q1 2026), $25.9 million (Q4 2025), and $21.6 million (Q3 2025), per Business Quant data.